As Vtesse announced today that the US Food and Drug Administration (FDA) has given its drug candidate VTS 270 for the treatment of Niemann-Pick disease type C1 (NPC) the "Breakthrough Therapy" status. See full article at finanzen.net
As Vtesse announced today that the US Food and Drug Administration (FDA) has given its drug candidate VTS 270 for the treatment of Niemann-Pick disease type C1 (NPC) the "Breakthrough Therapy" status. See full article at finanzen.net